Tracking 6 vendors · 83 listings · checked Aug 02Current partner codePEPTIDESDE

InvestigationalWeight lossSubcutaneousEvidence 4/5

Cagrilintide

Also known as: AM833

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Browse research guides View clinical trials Buy / compare source

Illustrative profileSubcutaneous

Database profileInvestigational

CagrilintideWeight loss

Drug class: Amylin analog
Primary targets: Amylin / CTR
Dose reference: Trial doses up to 4.5 mg weekly
Half-life: ~7 days
Developer / origin: Novo Nordisk
Reference year: 2021
Evidence score: 4/5 - Phase 2 human evidence

Evidence 4/5

Phase 2 human evidence

Cagrilintide has randomized phase 2 human weight-management data and combination evidence with semaglutide, but it remains investigational.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

Human phase 2 obesity trial
CagriSema clinical development
No approved indication yet

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Cagrilintide guides

Read the matching guide or adjacent research pages for more context.

CagriSema: Cagrilintide + Semaglutide Trial Results, Status and LimitsCagriSema is Novo Nordisk’s investigational amylin + GLP-1 combination. Trial averages look strong, but it is not approved and is not a DIY stack of research vials.Pramlintide: Amylin Analog Evidence, Weight Loss and Safety LimitsPramlintide is the approved amylin analog behind Symlin, but its weight-loss story is narrower than newer obesity-amylin marketing suggests.Cagrilintide: Amylin Evidence, CagriSema Results and SafetyCagrilintide is an investigational amylin analog. The strongest interest is CagriSema, Novo Nordisk's cagrilintide plus semaglutide combination.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.

Cagrilintide calculator shortcuts

Open peptide calculators with editable Cagrilintide example values already filled in.

Cagrilintide accumulation calculatorPrefills 168 hour half-life and 168 hour interval examples.Open prefilled tool

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open tool Peptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open tool Peptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open tool Peptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5

Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5

Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5

Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Liraglutide

Victoza, Saxenda

5/5

Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →